109 related articles for article (PubMed ID: 23334989)
1. Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.
Yang Y; Bykadi S; Carlin AS; Shah RB; Yu LX; Khan MA
J Pharm Sci; 2013 Apr; 102(4):1370-81. PubMed ID: 23334989
[TBL] [Abstract][Full Text] [Related]
2. Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients.
How PP; Anattiwong P; Mason DL; Arruda JA; Lau AH
Hemodial Int; 2011 Jan; 15(1):95-9. PubMed ID: 21138519
[TBL] [Abstract][Full Text] [Related]
3. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
Autissier V; Damment SJ; Henderson RA
J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
[TBL] [Abstract][Full Text] [Related]
4. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
Schumacher SP; Schurgers LJ; Vervloet MG; Neradova A
Nephrology (Carlton); 2019 Feb; 24(2):221-226. PubMed ID: 29479762
[TBL] [Abstract][Full Text] [Related]
5. Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
Mukai I; Yoshizawa T; Kumagai J; Takahashi N; Tsuchiya S
Ther Apher Dial; 2014 Jun; 18 Suppl 1():28-33. PubMed ID: 24953764
[TBL] [Abstract][Full Text] [Related]
6. [Lanthanum carbonate in clinical practice].
Torregrosa Prats V
Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
[TBL] [Abstract][Full Text] [Related]
7. In vitro bioequivalence approach for a locally acting gastrointestinal drug: lanthanum carbonate.
Yang Y; Shah RB; Yu LX; Khan MA
Mol Pharm; 2013 Feb; 10(2):544-50. PubMed ID: 23249191
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lanthanum carbonate in German patients on dialysis.
Dellanna F; Reichel H; Seibt F
Clin Nephrol; 2012 Nov; 78(5):382-90. PubMed ID: 22948119
[TBL] [Abstract][Full Text] [Related]
9. Effects of efficient phosphate binding on bone in chronic renal failure rats.
Behets GJ; Gritters M; Dams G; De Broe ME; D'Haese PC
Ren Fail; 2005; 27(4):475-84. PubMed ID: 16060138
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients.
Sakurada T; Oishi D; Shibagaki Y; Yasuda T; Kimura K
Hemodial Int; 2013 Oct; 17 Suppl 1():S2-6. PubMed ID: 24134326
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of in vitro efficacy of colesevelam hydrochloride tablets.
Krishnaiah YS; Yang Y; Bykadi S; Sayeed VA; Khan MA
Drug Dev Ind Pharm; 2014 Sep; 40(9):1173-9. PubMed ID: 23805883
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonate.
Samy R; Faustino PJ; Adams W; Yu L; Khan MA; Yang Y
J Pharm Biomed Anal; 2010 Apr; 51(5):1108-12. PubMed ID: 20031362
[TBL] [Abstract][Full Text] [Related]
13. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
14. Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.
Pierce D; Hossack S; Robinson A; Zhang P; Martin P
Clin Ther; 2012 Jun; 34(6):1290-1300.e2. PubMed ID: 22657252
[TBL] [Abstract][Full Text] [Related]
15. Is granular formulation of lanthanum carbonate more effective than chewable tablets?
Okamoto H; Haruhara K; Kamejima S; Mafune H; Manabe M; Kanzaki G; Mashiko H; Yokoo T
Ther Apher Dial; 2014 Jun; 18 Suppl 1():23-7. PubMed ID: 24953763
[TBL] [Abstract][Full Text] [Related]
16. Effects of change in the formulation of lanthanum carbonate on laboratory parameters.
Takita T; Furuhashi M; Fujimoto T; Suzuki H; Harada M; Maruyama S; Tamiya R; Kamiya E; Okamoto M; Tukada A; Furuhashi M; Kato A
Ther Apher Dial; 2014 Jun; 18 Suppl 1():18-22. PubMed ID: 24953762
[TBL] [Abstract][Full Text] [Related]
17. Chewability testing in the development of a chewable tablet for hyperphosphatemia.
Lanz M; Baldischweiler J; Kriwet B; Schill J; Stafford J; Imanidis G
Drug Dev Ind Pharm; 2014 Dec; 40(12):1623-31. PubMed ID: 24010939
[TBL] [Abstract][Full Text] [Related]
18. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
Neven E; Dams G; Postnov A; Chen B; De Clerck N; De Broe ME; D'Haese PC; Persy V
Nephrol Dial Transplant; 2009 Jun; 24(6):1790-9. PubMed ID: 19144999
[TBL] [Abstract][Full Text] [Related]
19. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Behets GJ; Dams G; Vercauteren SR; Damment SJ; Bouillon R; De Broe ME; D'Haese PC
J Am Soc Nephrol; 2004 Aug; 15(8):2219-28. PubMed ID: 15284308
[TBL] [Abstract][Full Text] [Related]
20. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
Gonzalez-Parra E; Gonzalez-Casaus ML; Galán A; Martinez-Calero A; Navas V; Rodriguez M; Ortiz A
Nephrol Dial Transplant; 2011 Aug; 26(8):2567-71. PubMed ID: 21436379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
